CA
NZ
UK
AU
IND
US
…
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
ACADIA Pharmaceuticals is a biopharma company focused on central nervous system disorders, commercializing pimavanserin (Nuplazid) for Parkinson's disease psychosis and pursuing additional neuropsychiatric indications. Long-term growth may be driven by potential label expansions, international commercialization and partnerships that could support revenue diversification, while investors should monitor clinical readouts and regulatory timelines.
Material risks include dependence on a single marketed product, trial failures, competition from other antipsychotics, and pricing, reimbursement or patent-exclusivity pressures.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 138.90M | 258.07M | -51.04M | -213.44M | -167.52M |
| Net income | 391.00M | 226.45M | -61.29M | -215.97M | -167.87M |
| Selling general administrative | 548.89M | 488.43M | 393.07M | 369.09M | 396.03M |
| Selling and marketing expenses | - | - | 9.40M | - | - |
| Gross profit | 982.51M | 875.96M | 680.71M | 507.07M | 465.00M |
| Reconciled depreciation | 11.76M | 15.88M | 5.55M | 2.03M | 3.34M |
| Ebit | - | 84.28M | -73.38M | -225.62M | -173.78M |
| Ebitda | 138.90M | 100.16M | -67.83M | -223.60M | -170.44M |
| Depreciation and amortization | - | 15.88M | 5.55M | 2.03M | 3.34M |
| Non operating income net other | - | - | - | - | -2.33M |
| Operating income | 104.81M | 230.79M | -73.38M | -223.60M | -170.44M |
| Other operating expenses | 966.69M | 727.00M | 799.82M | 740.83M | 654.58M |
| Interest expense | - | - | - | 6.61M | 6.26M |
| Tax provision | -252.10M | 31.62M | 10.25M | 2.53M | 0.35M |
| Interest income | 31.72M | 25.46M | 17.23M | 6.61M | 0.59M |
| Net interest income | 31.72M | 25.46M | 17.23M | 6.61M | 0.59M |
| Income tax expense | -252.10M | 31.62M | 10.25M | 2.53M | 0.35M |
| Total revenue | 1071.51M | 957.80M | 726.44M | 517.24M | 484.14M |
| Total operating expenses | 877.70M | 645.16M | 754.09M | 730.66M | 635.44M |
| Cost of revenue | 89.00M | 81.84M | 45.73M | 10.17M | 19.14M |
| Total other income expense net | 34.09M | 27.28M | 22.34M | 10.15M | 2.92M |
| Net income from continuing ops | 391.00M | 226.45M | -61.29M | -215.97M | -167.87M |
| Net income applicable to common shares | - | - | - | -215.97M | -167.87M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1564.19M | 1187.76M | 748.96M | 587.81M | 700.12M |
| Intangible assets | 108.89M | 119.78M | 65.49M | - | - |
| Other current assets | 59.53M | 55.68M | 39.09M | 21.40M | 23.89M |
| Total liab | 336.81M | 454.96M | 317.20M | 187.40M | 159.23M |
| Total stockholder equity | 1227.39M | 732.79M | 431.75M | 400.41M | 540.89M |
| Other current liab | 254.88M | 356.70M | 225.74M | 103.58M | 80.89M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Capital stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -1813.39M | -2204.39M | -2430.84M | -2369.55M | -2153.58M |
| Other liab | - | - | - | 9.07M | 7.03M |
| Good will | - | - | 0.00M | - | - |
| Other assets | - | - | - | 11.08M | 15.98M |
| Cash | 177.69M | 319.59M | 188.66M | 114.85M | 147.44M |
| Total current liabilities | 277.11M | 394.87M | 254.25M | 125.63M | 96.07M |
| Current deferred revenue | - | - | 1.56M | - | - |
| Net debt | -125.51M | -267.59M | -131.45M | -52.85M | -91.31M |
| Short term debt | 11.63M | 9.96M | 9.40M | 9.30M | 8.30M |
| Short long term debt total | 52.19M | 51.99M | 57.20M | 62.00M | 56.13M |
| Other stockholder equity | 3039.32M | 2936.87M | 2862.55M | 2770.92M | 2694.65M |
| Property plant equipment | - | - | - | 61.59M | 66.31M |
| Total current assets | 1062.11M | 938.32M | 616.12M | 507.94M | 617.82M |
| Net tangible assets | - | - | - | 400.41M | 540.89M |
| Short term investments | 641.99M | 436.40M | 250.21M | 301.98M | 373.27M |
| Net receivables | 148.23M | 104.69M | 102.35M | 63.08M | 65.34M |
| Inventory | 34.67M | 21.95M | 35.82M | 6.64M | 7.88M |
| Accounts payable | 10.90M | 16.19M | 17.54M | 12.75M | 6.88M |
| Accumulated other comprehensive income | 1.45M | 0.29M | 0.02M | -0.97M | -0.19M |
| Common stock total equity | - | - | - | - | 0.02M |
| Retained earnings total equity | - | - | - | - | -2153.58M |
| Non currrent assets other | 80.60M | 78.87M | 5.10M | 18.28M | 15.98M |
| Non current assets total | 502.08M | 249.44M | 132.83M | 79.88M | 82.30M |
| Capital lease obligations | 52.19M | 51.99M | 57.20M | 62.00M | 56.13M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -199.04M | -30.54M | 32.00M | 73.24M | -69.98M |
| Change to liabilities | - | - | - | 5.87M | -8.22M |
| Total cashflows from investing activities | -302.56M | -30.54M | 32.00M | 73.24M | -71.10M |
| Total cash from financing activities | 49.88M | 6.84M | 25.13M | 8.20M | 18.16M |
| Change to operating activities | - | - | - | 27.54M | -2.88M |
| Net income | 391.00M | 226.45M | -61.29M | -215.97M | -167.87M |
| Change in cash | -141.89M | 133.93M | 73.81M | -32.59M | -178.59M |
| Begin period cash flow | 319.59M | 194.43M | 114.85M | 153.21M | 331.80M |
| End period cash flow | 177.69M | 328.36M | 188.66M | 120.62M | 153.21M |
| Total cash from operating activities | 109.84M | 157.72M | 16.70M | -114.03M | -125.66M |
| Issuance of capital stock | 49.88M | 6.84M | 25.13M | 8.20M | 18.16M |
| Depreciation | 11.76M | 15.88M | 5.55M | 2.03M | 3.34M |
| Other cashflows from investing activities | - | 146.51M | 32.05M | - | - |
| Change to inventory | -18.20M | -49.55M | -28.81M | 2.42M | -4.21M |
| Change to account receivables | -43.54M | -2.35M | -39.27M | 2.17M | -16.12M |
| Sale purchase of stock | - | - | - | - | 18.16M |
| Other cashflows from financing activities | - | - | 32.00M | 73.24M | -71.10M |
| Change to netincome | - | - | - | 61.92M | 61.29M |
| Capital expenditures | 4.69M | 0.52M | 40.05M | 0.00M | 1.12M |
| Change receivables | - | - | - | - | -15.06M |
| Cash flows other operating | - | - | - | - | 2.67M |
| Cash and cash equivalents changes | - | - | - | - | -178.60M |
| Change in working capital | -89.76M | 4.16M | 18.13M | 37.99M | -24.82M |
| Stock based compensation | 52.13M | 67.05M | 66.42M | 68.20M | 63.62M |
| Other non cash items | 46.71M | -155.82M | -12.12M | -6.28M | 0.07M |
| Free cash flow | 105.15M | 157.20M | -23.35M | -114.03M | -126.78M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals Inc |
0.44 2.17% |
20.76 | 12.33 | 27.25 | 4.02 | 3.63 | 3.39 | 39.21 |
| NVO Novo Nordisk A/S |
0.85 2.22% |
39.14 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
10.31 1.95% |
540.00 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.50 0.68% |
818.77 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen R. Davis J.D. | CEO & Director | 1961 |
| Dr. Srdjan R. Stankovic M.D., M.S.P.H. | Pres | 1957 |
| Mr. Mark C. Schneyer | Exec. VP & CFO | 1974 |
| Mr. Brendan P. Teehan | Exec. VP, COO & Head of Commercial | 1969 |
| Mr. Austin D. Kim | Exec. VP, Gen. Counsel & Sec. | 1964 |
| Mr. James K. Kihara | VP, Chief Accounting Officer & Corp. Controller | 1981 |
| Mr. Bob Mischler | Sr. VP of Strategy & Technology Operations | NA |
| Mr. Mark C. Johnson | VP of Investor Relations | NA |
| Ms. Julie Fisher | Sr. VP of Marketing & Commercial Strategy | NA |
| Mr. Rob Ackles | Sr. VP & Chief People Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.52%
Communication Services
+0.32%
Consumer Cyclical
+1.01%
Consumer Defensive
+0.00%
Energy
+0.01%
Financial Services
+0.62%
Financials
-2.62%
Healthcare
+0.51%
Industrials
+0.71%
Real Estate
+0.72%
Technology
-0.46%
Utilities
+0.54%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...